jcm-logo

Journal Browser

Journal Browser

Lung Transplantation: Clinical Advances and Practice Updates

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".

Deadline for manuscript submissions: 25 September 2025 | Viewed by 438

Special Issue Editor


E-Mail Website
Guest Editor
1. The Sheba Lung Transplant Program, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
2. Department of Thoracic Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
Interests: lung transplantation; VATS; inflammatory diseases of the pleura; pediatric general thoracic surgery; lung volume reduction surgery; lung cancer; mesothelioma

Special Issue Information

Dear Colleagues,

The last decade brought about a huge improvement in lung transplantation. The rise in ex vivo lung perfusion presented a tremendous development in recovering borderline donor lungs, bringing about an increase in the number of transplants that occur. The COVID-19 pandemic resulted in new possibilities opening up in the field in ECMO and live-saving procedures, and we found that patients in prolonged extra-corporeal circulation could be transplanted with very good results.

In recent years, the use of DCD donor lungs has become common practice in many centers, and living related donation has become a more common practice, though it is only used in a few centers around the world. New drugs being developed and alterations of the blood type of the lungs are making our specialty increasingly thrilling.

The purpose of this Special Issue is to present original work centered around these new achievements. We would like to share with our readers these new modalities, techniques, and treatments that have the potential to significantly improve our therapeutic strategies.

Dr. Milton Saute
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung transplantation
  • respiratory failure
  • thoracic surgery
  • cardiothoracic surgery
  • solid organ transplantation
  • immunosuppression
  • lung cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 916 KiB  
Article
Accessing the Impacts of the Calculated Panel Reactive Antibody Value on a Lung Transplant Waitlist: A Latin American Experience
by Samuel Lucas dos Santos, Flavio Pola dos Reis, Luis Gustavo Abdalla, Lucas Matos Fernandes, Elissa Ayumi Okuno, Priscila Cilene Leon Bueno Camargo, Rafael Medeiros Carraro, Silvia Vidal Campos, Ricardo Henrique Oliveira Braga Teixeira and Paulo Manuel Pêgo-Fernandes
J. Clin. Med. 2025, 14(12), 4344; https://doi.org/10.3390/jcm14124344 - 18 Jun 2025
Viewed by 196
Abstract
Backgorund\Objectives: Lung transplantation is the definitive treatment for select patients with end-stage pulmonary diseases. However, immunologic sensitization, as measured by calculated panel-reactive antibody (cPRA), poses significant challenges to transplant access and outcomes. This study aimed to evaluate the impact of cPRA on lung [...] Read more.
Backgorund\Objectives: Lung transplantation is the definitive treatment for select patients with end-stage pulmonary diseases. However, immunologic sensitization, as measured by calculated panel-reactive antibody (cPRA), poses significant challenges to transplant access and outcomes. This study aimed to evaluate the impact of cPRA on lung transplantation waitlist dynamics in a single-center cohort in Brazil, focusing on its association with waitlist mortality, delisting, and transplantation. Methods: A retrospective cohort study was conducted including all lung transplant candidates listed in our institution between January 2012 and December 2022. Candidates were stratified by cPRA values at listing into five groups: 0%, 0.1–25%, 25.1–50%, 50.1–75%, and 75.1–100%. Primary outcomes included lung transplantation, with secondary outcomes of waitlist mortality and delisting due to clinical deterioration. Statistical comparisons were performed, as appropriate. Results: Of the 411 candidates evaluated, 327 met the inclusion criteria. Among them, 100 (30.6%) were sensitized (cPRA > 0%), with increasing cPRA values correlating with longer median waitlist times (p < 0.01). Although transplantation rates were not statistically different across the cPRA strata (p = 0.277), the group with a cPRA > 75% had the lowest transplant rate (37.5%). Waitlist mortality was significantly higher in candidates with a cPRA > 50% (p = 0.047), whereas delisting rates did not differ across groups (p = 0.722). Conclusions: Elevated cPRA is associated with prolonged waitlist time and increased mortality, reflecting both immunologic and logistical barriers to lung transplantation. These findings support the need for incorporating cPRA into allocation policies and adopting targeted strategies, such as desensitization protocols, to improve equity in transplant access for sensitized patients, particularly in genetically diverse populations. Further multicenter studies are warranted to validate these results and inform policy development. Full article
(This article belongs to the Special Issue Lung Transplantation: Clinical Advances and Practice Updates)
Show Figures

Figure 1

Back to TopTop